Complete remission following recombinant interferon alpha-2a in a patient with diffuse large B cell cutaneous lymphoma.
Recombinant interferon alpha (r IFN alpha) has shown significant antitumor activity in patients with follicular small cleaved cell (low-grade non-Hodgkin's lymphomas) and cutaneous T-cell lymphomas. However, IFN alpha seems to be less effective in patients with intermediate or high-grade lymphomas. This case report describes a patient with an initial diagnosis of low grade B-cell lymphoma with histologic conversion to diffuse large B-cell (B1+, Kappa+) cutaneous lymphoma. This tumor proved refractory to chemotherapy but a complete and durable remission was induced with R IFN alpha 2a treatment.
Tourani
J M
JM
Oncology and Hematology Unit, Laennec Hospital, Paris, France.
Leaute
J B
JB
Lessana-Leibowitch
M
M
Andrieu
J M
JM
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001402:B-Lymphocytes; D003131:Combined Modality Therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015182:Lymphatic Irradiation; D008223:Lymphoma / Q000628:therapy*; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D009378:Neoplasms, Multiple Primary; D011994:Recombinant Proteins; D012074:Remission Induction; D012878:Skin Neoplasms / Q000628:therapy*
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins